Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Change in Accured Expenses for 6 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 38.53% to $5.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.4 million, a 68.64% decrease, with the full-year FY2024 number at $6.5 million, up 93.53% from a year prior.
  • Change in Accured Expenses was $5.0 million for Q3 2025 at 4D Molecular Therapeutics, up from $3.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.1 million in Q3 2024 to a low of -$3.4 million in Q1 2023.
  • A 5-year average of $992052.6 and a median of $1.1 million in 2021 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 1881.48% in 2021; the steepest drop was 339.27% in 2021.
  • 4D Molecular Therapeutics' Change in Accured Expenses stood at $535000.0 in 2021, then skyrocketed by 240.75% to $1.8 million in 2022, then rose by 9.54% to $2.0 million in 2023, then crashed by 218.48% to -$2.4 million in 2024, then soared by 310.57% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Change in Accured Expenses are $5.0 million (Q3 2025), $3.1 million (Q2 2025), and -$2.3 million (Q1 2025).